Balentine LLC Abb Vie Inc. Transaction History

Balentine LLC

$2.54 Billion
Q3 2024

A detailed history of Balentine LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Balentine LLC holds 10,842 shares of ABBV stock, worth $1.95 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

10,842

Previous 5,786 87.38%

Holding current value

$1.95 Million

Previous $992,000 115.83%

% of portfolio

0.08%

Previous 0.05%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$163.84 - $199.33 $828,375 - $1.01 Million	5,056 Added 87.38%	10,842 $2.14 Million
Q2 2024 Aug 07, 2024	SELL	$154.79 - $180.76 $5.17 Million - $6.03 Million	-33,385 Reduced 85.23%	5,786 $992,000
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $535,077 - $609,670	3,348 Added 9.35%	39,171 $7.13 Million
Q4 2023 Feb 09, 2024	BUY	$137.6 - $154.97 $943,523 - $1.06 Million	6,857 Added 23.67%	35,823 $5.55 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $679,973 - $787,168	5,090 Added 21.32%	28,966 $4.32 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $327,564 - $407,632	2,472 Added 11.55%	23,876 $3.22 Million
Q1 2023 May 11, 2023	SELL	$144.61 - $166.54 $866,936 - $998,407	-5,995 Reduced 21.88%	21,404 $3.41 Million
Q4 2022 Jan 31, 2023	BUY	$138.31 - $165.87 $318,389 - $381,832	2,302 Added 9.17%	27,399 $4.43 Million
Q3 2022 Oct 26, 2022	SELL	$134.21 - $153.93 $7.74 Million - $8.87 Million	-57,654 Reduced 69.67%	25,097 $3.37 Million
Q2 2022 Oct 26, 2022	BUY	$137.62 - $174.96 $9.38 Million - $11.9 Million	68,159 Added 467.1%	82,751 $12.7 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $9.38 Million - $11.9 Million	68,159 Added 467.1%	82,751 $12.7 Million
Q1 2022 Oct 26, 2022	SELL	$131.98 - $163.75 $9 Million - $11.2 Million	-68,159 Reduced 82.37%	14,592 $2.37 Million
Q1 2022 May 06, 2022	BUY	$131.98 - $163.75 $359,513 - $446,055	2,724 Added 22.95%	14,592 $2.37 Million
Q4 2021 Oct 26, 2022	SELL	$107.43 - $135.93 $7.61 Million - $9.64 Million	-70,883 Reduced 85.66%	11,868 $1.61 Million
Q4 2021 Feb 02, 2022	BUY	$107.43 - $135.93 $304,886 - $385,769	2,838 Added 31.43%	11,868 $1.61 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $6,384 - $7,246	-60 Reduced 0.66%	9,030 $974,000
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $68,176 - $75,952	-648 Reduced 6.65%	9,090 $1.02 Million
Q1 2021 May 10, 2021	BUY	$102.3 - $112.62 $119,281 - $131,314	1,166 Added 13.6%	9,738 $1.05 Million
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $54,652 - $73,786	-679 Reduced 7.34%	8,572 $918,000
Q3 2020 Nov 02, 2020	BUY	$85.91 - $100.83 $528,088 - $619,802	6,147 Added 198.03%	9,251 $810,000
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $807 - $1,079	-11 Reduced 0.35%	3,104 $305,000
Q1 2020 May 18, 2020	BUY	$64.5 - $97.79 $64,758 - $98,181	1,004 Added 47.56%	3,115 $237,000
Q4 2019 Sep 02, 2020	BUY	$72.13 - $90.25 $28,347 - $35,468	393 Added 22.88%	2,111 $187,000
Q3 2019 Nov 15, 2019	BUY	$62.98 - $75.72 $71,734 - $86,245	1,139 Added 196.72%	1,718 $130,000
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $55,713 - $71,215	-848 Reduced 59.43%	579 $42,000
Q1 2019 May 16, 2019	BUY	$77.14 - $90.79 $6,325 - $7,444	82 Added 6.1%	1,427 $115,000
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $98,791 - $121,836	1,269 Added 1669.74%	1,345 $124,000
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $6,823 - $8,073	76 New	76 $7,000
Q1 2018 May 16, 2018	SELL	$92.01 - $123.21 $74,068 - $99,184	-805 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $1,432 - $1,571	16 Added 2.03%	805 $78,000
Q3 2017 Nov 15, 2017	BUY	$69.85 - $89.22 $55,111 - $70,394	789	789 $70,000

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balentine LLC with notifications on news.

Account